-Bloomberg
BTIG Maintains Buy on LumiraDx, Lowers Price Target to $4
BTIG analyst Mark Massaro maintains LumiraDx (NASDAQ:LMDX) with a Buy and lowers the price target from $7 to $4.
Related Posts
Why Rocket Lab Stock Is Moving Higher After Hours
Rocket Lab USA Inc (NASDAQ: RKLB) shares are taking off in Monday's after-hours session after the company announced it signed a launch
CareCloud’s medSR Division Successfully Implements MEDITECH Expanse EHR At Doctors Hospital Bahamas, Enhancing Patient Care And Data Resilience
CareCloud, Inc. (NASDAQ:CCLD, CCLDP, CCLDO)))), a leader in healthcare technology services for medical practices and health systems nationwide, today announced its medSR division recently completed the successful
Fuwei Films Announces Results Of General Meeting In September 2022
BEIJING, Sept. 26, 2022 /PRNewswire/ -- Fuwei Films (Holdings) Co., Ltd. (NASDAQ:FFHL) ("Fuwei Films" or the "Company"), a manufacturer and distributor of high-quality BOPET plastic